Defective Drug Litigation Funding

TriMark Legal Funding is one of America’s top-rated lawsuit funding companies. We provide low-cost pre-settlement lawsuit loans to injury victims with defective drug lawsuits nationwide.

It’s Fast, Free & Easy To Qualify For Legal Funding

With each new pharmaceutical lawsuit, new light is shed on the ever-blurring lines between consumer protection and the FDA.

Not to mention the fading line between consumer safety and the ever-widening chasm of corporate greed, non-accountability and irresponsibility.

Pharmaceutical lawsuits are nothing new. What is new, and quite troubling however, is the ever-increasing size, scope, lethality and regularity with which new defective drug lawsuits are being introduced.

Perhaps most disturbing of all is the growing trend of MDL drug lawsuits being brought against pharmaceutical companies who are often shown to have been fully aware that their products had serious, even deadly side effects, but chose to ignore the human costs and market them anyway because of the multi-billion dollar profit potential. They just fail to provide adequate consumer warnings.

When did that become okay? Isn’t litigation meant to punish the offenders? If so, why does this trend seem to be gaining momentum instead of losing it? The all-too-obvious rationale is as outrageous as it is unconscionable; pursue the almighty dollar no matter the cost in human lives and suffering.

The pattern so far has been easy enough to spot; big pharmaceuticals earn tens of billions of dollars in profits by mass marketing a new drug for a few years and then write off the human losses and inevitable litigation expenses as simply the cost of doing business.

Historically, multi-billion-dollar litigation and settlement expenses tend to consume only a tiny fraction of a heavily-marketed pharmaceutical product’s overall profit run. So companies retain billions in profit after the dust settles; not much of an effective punishment or deterrent.

In addition, this provides zero incentive for pharmaceuticals companies to act responsibly or police themselves. To the contrary, it provides an enormous and clearly irresistible financial incentive to continue this despicable practice unabated.